engleski

ORAL CONTRACEPTIVES THERAPY IN POLYCYSTIC OVARY SYNDROME: THE EFFECTS ON HORMONAL STATUS AND OVARIAN RESERVE

Introduction: Our aim was to show whether three months of therapy with oral contraceptives changed the hormonal status of patients with polycystic ovary syndrome (PCOS). The concentration of Anti- Müllerian hormone (AMH), as one of the parameters of ovarian reserve, was also measured. Materials and Methods: The study included 19 patients with PCOS and clinical/laboratory signs of hyperandrogenism without additional comorbidity and therapy. All participants were treated with the same therapy (a fixed combination of ethinyl estradiol (0.035 mg) and cyproterone acetate (2 mg)). The main outcome measures were concentrations of reproductive hormones measured before the therapy and during the first menstrual cycle after the end of the therapy, as well as age, body height, weight and body mass index. Hormone concentrations were analyzed by the immunochemical electrochemiluminiscent method (ECLIA). Results: Mean age of the participants was 29 years, body weight 69 kg, and body mass index 24.2 kg / m2. Initial concentrations of total and free testosterone, and AMH were elevated while those of other reproductive hormones were within reference range. Due to the treatment, AMH, luteinizing hormone and estradiol concentration decreased by 20% and free testosterone by more than 85%. Expectedly, the concentration of sex- hormone binding globulin increased by 40%. Conclusions: Based on our results, three months of oral contraceptives therapy induced changes in the concentration of reproductive hormones and apparently slightly reduced the ovarian reserve. However, for better assessment of ovarian reserve, further research based on a longer-term monitoring of the patients’ hormonal status with PCOS is needed.

ORAL CONTRACEPTIVES THERAPY, POLYCYSTIC OVARY SYNDROME, OVARIAN RESERVE

nije evidentirano